Characteristics, temporal trends and outcomes of Clostridioides difficile infection among hospitalized patients in Spain, 2016–2022 Authors: Maria-Jose Fernandez-Cotarelo, Cesar Henriquez-Camacho, Valentin Hernandez-Barrera, Angel Gil-de-Miguel Published: 2026 ABSTRACT BackgroundClostridioides difficile infection (CDI) is one of the most prevalent hospital-acquired infections, causing high morbidity and mortality. While incidence rates have recently increased in many countries, its epidemiology after the COVID-19 pandemic has yet to be determined. This study analyzes the characteristics and evolution of CDI in hospitalized patients in Spain.MethodsThis retrospective observational study was based on coded hospital discharge reports between 2016 and 2022 using the national hospital discharge database (MBDS), ICD-10 code A04.7. The variables analyzed were sex, age, comorbidities, diagnoses at discharge, procedures, overall severity, whether CDI was coded as a primary or secondary diagnosis, admission to the intensive care unit (ICU), length of stay, and in-hospital all-cause mortality.ResultsThere were 66,864 CDI cases (52.8% in women), affecting 0.22% of admissions. The mean age (70.4 years) and mean Charlson comorbidity index (2.49) increased over time. The overall rate per 1,000 admissions and the population-based mean incidence rate almost doubled between 2016 and 2022. Most cases (61.2%) were secondary cases. These patients were younger, more frequently admitted to the ICU, had higher comorbidity, more colectomies, and longer hospital stays. Overall mortality was 11.3%, significantly higher in secondary CDI, and it peaked in 2020. In-hospital all-cause mortality was higher in older patients (OR 1.04), those with more comorbidities (OR 1.14), those in the ICU (OR 28.54) and those with moderate (OR 1.54), high (OR 3.77), or extreme overall severity (OR 10.39).ConclusionsThe CDI incidence has increased in Spain. Age, comorbidities, overall severity, and admission to the ICU predicted poor outcomes in hospitalized patients with CDI. Preventive measures are warranted to decrease the disease burden.Clinical trialNot applicable. Introduction Clostridioides difficile infection (CDI) is one of the most prevalent hospital-acquired infections, accounting for more than 120,000 cases in acute-care hospitals and 3,700 direct deaths annually in Europe [1]. A multicenter study estimated the potential underdiagnoses of as many as 40,000 in-hospital cases in Europe [2]. A recent systematic review showed an incidence rate of healthcare-related CDI (HA-CDI) of 1.99 to 6.18 per 10,000 patient-days in Europe, with notable differences among countries, and 8 cases per 10,000 patient-days in the US [3]. A descriptive study conducted in France between 2010 and 2017 showed an increase in CDI incidence, which remained below the European average [4]. In Germany, there was a steady increase, peaking in 2015, and decreasing thereafter until 2021, with an incidence of 4.3 per 10,000 patient-days [5]. No general trend was detected in Europe from 2018 to 2020. These data must be interpreted cautiously because of irregular reporting during the COVID-19 pandemic [6]. The highest incidence has been reported in risk settings such as Internal Medicine wards and Critical Care units, with medians of 11.08 and 10.8 cases per 1,000 admissions per year, respectively [7]. In the US, a study by the Emerging Infections Program estimated a decrease in the burden of CDI and hospitalizations from 2011 to 2017 [8]. Recent data confirmed an exponential increase in CDI cases in Spain since 2012, reaching 35.9 per 10,000 hospitalized patients in 2019 [9]. A study based on the Minimum Basic Data Set (MBDS) including nearly 50,000 hospital discharges between 2001 and 2015, showed that the rate of hospitalizations for CDI almost tripled. The mean age of the patients, severity, costs and readmission rate increased, but LOS and mortality decreased over the study period. Mortality was associated with male sex, older age, comorbidities, severity and readmission [10]. The analysis of more than 7,200 cases in Internal Medicine wards in Spain showed an increasing annual incidence; among these patients, older than in other reports, CDI increased mortality by 30% and almost doubled the readmission rate. The risk factors for CDI were advanced age, female sex, admission from long-term care facilities, comorbidities, and prolonged hospital stay [11]. A study based on the Spanish EPINE epidemiological surveillance system that showed an annual increase of 11% in the prevalence of CDI between 2012 and 2019 showed factors such as neutropenia, immunodeficiency, cirrhosis, renal failure, and neoplasms associated with CDI regardless of age [9]. Recently, Garcia-Carretero et al. provided information on the geographical distribution of CDI in Spain, adding data on recurrences [12]. However, there is a lack of detailed analysis, including patient characteristics, such as the burden of comorbidities, presence of inflammatory bowel disease (IBD), need for colectomy, and severity. The COVID pandemic has impacted patient care and infection prevention and control practices, influencing healthcare-associated infections (HAI) [13]. The ECDC surveillance report showed a mean incidence density for healthcare-associated CDI of 2.79, 2.02 and 2.58 cases per 10,000 patient-days in 2018, 2019, and 2020, respectively. For community-associated or unknown association CDI, the reported mean hospital incidence was 0.69 cases per 1,000 patient discharges or admissions in 2018 and 2019, rising to 1.35 in 2020. However, owing to insufficient reporting during the pandemic, definitive conclusions regarding its influence on CDI epidemiology in Europe are not available [6]. Factors such as changes in hospital admissions, antibiotic use, and infection control measures are considered to have influenced the epidemiology of CDI during the pandemic. A review of publicly available data of CDI cases from 13 countries reported an overall decrease in hospital-based cases over the last 15 years, whereas population-based figures showed an increase since 2020 in many countries [14]. During and after the COVID pandemic there was an increase in HAI in the US, except for CDI, which decreased [13, 15]. Nonetheless, mortality in patients with CDI was higher during the pandemic than that in the pre-COVID-19 period [16]. The costs associated with infection are mostly attributable to extended LOS. A recent review showed varying hospital cost estimates from different European studies, exceeding €12,000 for primary episodes in some cases [17]. Recurrent CDI has also been shown to prolong LOS and increase admission costs by more than €10,000 per episode [18]. The economic burden in the European Union is estimated to be €300 million annually [3]. While CDI continues to represent a threat to our Healthcare System, there is need of detailed information of the infection in hospitalized patients. This study aimed to analyze the epidemiology of CDI in hospitals in Spain over 7 years, with a comprehensive assessment including patient characteristics, comparison of primary vs. secondary cases, in-hospital mortality, and temporal trends. Methods We conducted a retrospective observational study based on hospital discharge records from the National Health System between 2016 and 2022, including all acute admissions to public and private hospitals. The Ministry of Health provided anonymized data upon request using the MBDS, including sex, date of birth, primary diagnosis, up to 13 secondary diagnoses at discharge, and procedures performed, coded according to the International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM], ICU admission, LOS, in-hospital all-cause mortality, and costs. The primary diagnosis is coded at discharge as the condition considered to be the main reason for admission, while the secondary diagnosis refers to conditions that develop during admission or comorbidities in patients hospitalized for other reasons. All admissions with a primary or secondary diagnosis of CDI (ICD-10-CM code A04.7) were included, with no age limit. More than one admission of the same patient was included if they had suffered from CDI more than once in the 7-year period analyzed. Comorbidity was assessed using the Charlson Comorbidity Index (CCI) and stratified into low (0–1), moderate (2), and high (≥ 3) comorbidity categories. Specific conditions, such as IBD, COVID-19, and surgical interventions, were also recorded. The severity in each admitted patient was stratified according to hospital discharge records from 1 (mild) to 4 (extremely severe), considering the patient characteristics, all diagnoses and procedures performed, and was not based on CDI severity alone. The costs of admission were calculated using the weights of the diagnosis-related groups (GRD) and not attributed to CDI only. Variables such as colectomy, length of stay, cost, and in-hospital all-cause mortality were considered outcomes. ICD is diagnosed following European guidelines regarding microbiological studies in patients with diarrhea, but no microbiological data were available in this study, nor were data on treatment or whether CDI was a first episode or a recurrence. Statistical analysis Statistical analyses were performed using Stata Statistical Software (Release 18). Quantitative variables are expressed as means and standard deviations (SD) or medians with interquartile ranges (IQR), and qualitative variables are expressed as percentages. Bivariate analysis according to year was performed using the chi-square test for linear trends (proportions), analysis of variance (means), and Kruskal-Wallis test (medians), as appropriate. Population-based incidence rates were estimated per 100,000 inhabitants according to data from the Spanish National Institute of Statistics. Trends in incidence rates were assessed using Poisson regression models adjusted for sex and age when appropriate. A univariate analysis was performed for variables potentially associated with in-hospital mortality. Variables with significant results in univariate analysis were analyzed in multivariable logistic regression of risk factors. Adjusted odds ratios and 95% confidence intervals were calculated. Estimates are expressed as odds ratios (OR) and 95% confidence intervals (CI). Ethics The study was conducted in accordance with the ethical safeguards established by Spanish Organic Law 3/2018 on the Protection of Personal Data and Guarantee of Digital Rights, the Declaration of Helsinki and its subsequent amendments, and the principles of Good Clinical Practice. The study was evaluated and granted exemption by the Research Ethics Committee of the Universidad Rey Juan Carlos. The researchers received anonymized data, and informed consent was not required. Results Between 2016 and 2022, 66,864 cases of CDI were reported in hospitalized patients in Spain. The overall rate was 2.17 per 1,000 admissions, which increased steadily from 2016 to 2022, except for a slight decline in 2019. Cases of CDI as the primary diagnosis followed the same pattern, as did cases stratified by sex (Fig. 1). The mean incidence was 20.3 cases per 100,000 population, with an increasing trend during the study period, which was more pronounced after 2020 (Fig. 2). Fig. 1Hospital-based incidence of CDI per 1,000 admissions in hospitals of the National Health System, all cases (A) and only primary diagnosis (B), 2016–2022 Hospital-based incidence of CDI per 1,000 admissions in hospitals of the National Health System, all cases (A) and only primary diagnosis (B), 2016–2022 Fig. 2Population-based incidence of CDI per 100,000 population in hospitals of the National Health System, all cases (A) and only primary diagnosis (B), 2016–2022 Population-based incidence of CDI per 100,000 population in hospitals of the National Health System, all cases (A) and only primary diagnosis (B), 2016–2022 Table 1 shows the characteristics of the cases over the years. Women accounted for 52.8% of the cases, with no significant change over time. The mean age was 70.4 years, which increased significantly during the study period. Patients over 80 years were the most affected age group throughout the study period, with the highest percentage reaching 41.2% in 2022. Most CDI cases (61.2%) were coded as secondary diagnosis in patients admitted for other causes. High comorbidity was present in 41.3% of patients and increased annually. Among the comorbidities in the CCI, chronic kidney disease was the most prevalent (26.5%), followed by congestive heart failure (18.8%), diabetes mellitus (18.1%), chronic obstructive pulmonary disease (15.7%), and cancer (14.1%). The frequencies of acute myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, diabetes with complications, kidney disease, and metastatic cancer increased over the study period. The vast majority of patients were hospitalized in medical wards, whereas only 1.4% of CDI cases were in the ICU. One in five patients underwent a surgical procedure during admission. COVID-19 and CDI occurred during the same admission in 3,045 cases. Patients with IBD accounted for 3.9% of CDI cases, with no significant change over time. Codified severity was high or extreme in 68.1% of patients, peaking in 2020 and 2021. Table 2 shows the outcomes of the cases during the study period. The median LOS was 13 days. Colectomy was performed in 0.4% of patients, with a non-significant decrease in frequency over time. The overall in-hospital all-cause mortality rate was 11.3%, which was highest in 2020. The mean cost per admission was € 8,580, which was significantly higher in 2020 and 2021. Table 1Characteristics of the cases of CDI in patients hospitalized in the National Health System, and their temporal evolution over the period 2016–20222016201720182019202020212022Totalp-valueTotal CDI cases6,8717,9098,9528,5759,48311,61813,45666,864< 0.001CDI per 1,000 admissions1.561.731.981.882.352.6932.17CDI per 100,000 population14.81719.218.22024.528.120.3Sex (%)Male3,243 (47.2)3,673 (46.4)4,251 (47.5)4,092 (47.7)4,523 (47.7)5,489 (47.3)6,316 (46.9)31,587 (47.2)0.633Female3,628 (52.8)4,236 (53.6)4,701 (52.5)4,483 (52.3)4,960 (52.3)6,129 (52.8)7,140 (53.1)35,277 (52.8)Mean age (SD)69.7 (20.1)69.8 (20)69.8 (19.9)70.1 (20.2)70.3 (19.5)70.9 (19.6)71.3 (19.9)70.4 (19.9)< 0.001Age group (%)<18246 (3.6)256 (3.2)289 (3.2)295 (3.4)306 (3.2)386 (3.3)454 (3.4)2,232 (3.3)< 0.00118–591,343 (19.6)1,593 (20.1)1,786 (20)1,661 (19.4)1,795 (18.9)2,049 (17.6)2,322 (17.3)12,549 (18.8)60–691,032 (15)1,161 (14.7)1,369 (15.3)1,291 (15.1)1,540 (16.2)1,858 (16)2,074 (15.4)10,325 (15.4)70–791,539 (22.4)1,793 (22.7)1,959 (21.9)1,927 (22.5)2,177 (23)2,595 (22.3)3,062 (22.8)15,052 (22.5)≥ 802,711 (39.5)3,106 (39.3)3,549 (39.6)3,401 (39.7)3,665 (38.7)4,730 (40.7)5,544 (41.2)26,706 (39.9)CDI as primary diagnosis (%)2,682(39)3,118 (39.4)3,661 (40.9)3,568 (41.6)3,436 (36.2)4,336 (37.3)5,172 (38.4)25,973 (38.8)< 0.001Mean CCI (SD)2.31(2.1)2.36 (2.1)2.42 (2.2)2.5 (2.2)2.57 (2.2)2.56 (2.2)2.6 (2.3)2.49 (2.2)< 0.001Charlson comorbidity index (%)0–12,797(40.7)3,155(39.9)3,483(38.9)3,248(37.9)3,477(36.7)4,338(37.3)4,882(36.3)25,380(38)< 0.00121,465(21.3)1,695(21.4)1,934(21.6)1,772(20.7)1,957(20.6)2,295(19.8)2,726(20.3)13,844(20.7)≥ 32,609(38)3,059(38.7)3,535(39.5)3,555(41.5)4,049(42.7)4,985(42.9)5,848(43.5)27,640(41.3)Hospital ward (%)Medical6,100 (88.8)7,013 (88.7)8,029 (89.7)7,713 (90)8,453 (89.2)10,349 (89.1)12,118 (90.3)59,775 (89.5)0.012Surgical622 (9.1)744 (9.4)759 (8.5)717 (8.4)841 (8.9)1,030 (8.9)1,096 (8.2)5,809 (8.7)ICU113 (1.6)112 (1.4)129 (1.3)115 (1.3)137 (1.5)184 (1.6)174 (1.3)964 (1.4)Others36 (0.4)40 (0.5)33 (0.5)30 (0.3)48 (0.4)48 (0.4)37 (0.2)272 (0.4)COVID-19(%)No6,871 (100)7,909 (100)8,952 (100)8,575 (100)9,037 (95.3)10,729 (92.3)11,746 (87.3)63,819 (95.4)< 0.000Yes----446 (4.7)889 (7.7)1,710 (12.7)3,045 (4.6)IBD (%)No6,627 (96.4)7,626 (96.4)8,616 (96.2)8,220 (95.9)9,086 (95.8)11,145 (95.9)12,941 (96.2)64,261 (96.1)0.151Yes244 (3.6)283 (3.6)336 (3.8)355 (4.1)397 (4.2)473 (4.1)515 (3.8)2,603 (3.9)SeverityLow533(7.8)619(7.8)682(7.6)642(7.5)512(5.4)685(5.9)1,143(8.5)4,816(7.2)< 0.001Moderate1,784(26)2,106(26.6)2,467(27.6)2,291(26.7)1,768(18.6)2,089(18)3,989(29.6)16,494(24.7)High3,197(46.5)3,599(45.5)4,037(45.1)3,992(46.6)4,572(48.2)5,540(47.7)5,357(39.8)30,294(45.3)Extreme1,357(19.7)1,585(20)1,766(19.7)1,650(19.2)2,631(27.7)3,304(28.4)2,967(22)15,260(22.8)Abbreviations: CDI: Clostridioides difficile infection, SD: standard deviation, CCI: Charlson comorbidity index, ICU: intensive care unit; COVID-19: Coronavirus D, IBD: inflammatory bowel disease Table 1Characteristics of the cases of CDI in patients hospitalized in the National Health System, and their temporal evolution over the period 2016–20222016201720182019202020212022Totalp-valueTotal CDI cases6,8717,9098,9528,5759,48311,61813,45666,864< 0.001CDI per 1,000 admissions1.561.731.981.882.352.6932.17CDI per 100,000 population14.81719.218.22024.528.120.3Sex (%)Male3,243 (47.2)3,673 (46.4)4,251 (47.5)4,092 (47.7)4,523 (47.7)5,489 (47.3)6,316 (46.9)31,587 (47.2)0.633Female3,628 (52.8)4,236 (53.6)4,701 (52.5)4,483 (52.3)4,960 (52.3)6,129 (52.8)7,140 (53.1)35,277 (52.8)Mean age (SD)69.7 (20.1)69.8 (20)69.8 (19.9)70.1 (20.2)70.3 (19.5)70.9 (19.6)71.3 (19.9)70.4 (19.9)< 0.001Age group (%)<18246 (3.6)256 (3.2)289 (3.2)295 (3.4)306 (3.2)386 (3.3)454 (3.4)2,232 (3.3)< 0.00118–591,343 (19.6)1,593 (20.1)1,786 (20)1,661 (19.4)1,795 (18.9)2,049 (17.6)2,322 (17.3)12,549 (18.8)60–691,032 (15)1,161 (14.7)1,369 (15.3)1,291 (15.1)1,540 (16.2)1,858 (16)2,074 (15.4)10,325 (15.4)70–791,539 (22.4)1,793 (22.7)1,959 (21.9)1,927 (22.5)2,177 (23)2,595 (22.3)3,062 (22.8)15,052 (22.5)≥ 802,711 (39.5)3,106 (39.3)3,549 (39.6)3,401 (39.7)3,665 (38.7)4,730 (40.7)5,544 (41.2)26,706 (39.9)CDI as primary diagnosis (%)2,682(39)3,118 (39.4)3,661 (40.9)3,568 (41.6)3,436 (36.2)4,336 (37.3)5,172 (38.4)25,973 (38.8)< 0.001Mean CCI (SD)2.31(2.1)2.36 (2.1)2.42 (2.2)2.5 (2.2)2.57 (2.2)2.56 (2.2)2.6 (2.3)2.49 (2.2)< 0.001Charlson comorbidity index (%)0–12,797(40.7)3,155(39.9)3,483(38.9)3,248(37.9)3,477(36.7)4,338(37.3)4,882(36.3)25,380(38)< 0.00121,465(21.3)1,695(21.4)1,934(21.6)1,772(20.7)1,957(20.6)2,295(19.8)2,726(20.3)13,844(20.7)≥ 32,609(38)3,059(38.7)3,535(39.5)3,555(41.5)4,049(42.7)4,985(42.9)5,848(43.5)27,640(41.3)Hospital ward (%)Medical6,100 (88.8)7,013 (88.7)8,029 (89.7)7,713 (90)8,453 (89.2)10,349 (89.1)12,118 (90.3)59,775 (89.5)0.012Surgical622 (9.1)744 (9.4)759 (8.5)717 (8.4)841 (8.9)1,030 (8.9)1,096 (8.2)5,809 (8.7)ICU113 (1.6)112 (1.4)129 (1.3)115 (1.3)137 (1.5)184 (1.6)174 (1.3)964 (1.4)Others36 (0.4)40 (0.5)33 (0.5)30 (0.3)48 (0.4)48 (0.4)37 (0.2)272 (0.4)COVID-19(%)No6,871 (100)7,909 (100)8,952 (100)8,575 (100)9,037 (95.3)10,729 (92.3)11,746 (87.3)63,819 (95.4)< 0.000Yes----446 (4.7)889 (7.7)1,710 (12.7)3,045 (4.6)IBD (%)No6,627 (96.4)7,626 (96.4)8,616 (96.2)8,220 (95.9)9,086 (95.8)11,145 (95.9)12,941 (96.2)64,261 (96.1)0.151Yes244 (3.6)283 (3.6)336 (3.8)355 (4.1)397 (4.2)473 (4.1)515 (3.8)2,603 (3.9)SeverityLow533(7.8)619(7.8)682(7.6)642(7.5)512(5.4)685(5.9)1,143(8.5)4,816(7.2)< 0.001Moderate1,784(26)2,106(26.6)2,467(27.6)2,291(26.7)1,768(18.6)2,089(18)3,989(29.6)16,494(24.7)High3,197(46.5)3,599(45.5)4,037(45.1)3,992(46.6)4,572(48.2)5,540(47.7)5,357(39.8)30,294(45.3)Extreme1,357(19.7)1,585(20)1,766(19.7)1,650(19.2)2,631(27.7)3,304(28.4)2,967(22)15,260(22.8)Abbreviations: CDI: Clostridioides difficile infection, SD: standard deviation, CCI: Charlson comorbidity index, ICU: intensive care unit; COVID-19: Coronavirus D, IBD: inflammatory bowel disease Characteristics of the cases of CDI in patients hospitalized in the National Health System, and their temporal evolution over the period 2016–2022 2,682 (39) 2,797 (40.7) 3,155 (39.9) 3,483 (38.9) 3,248 (37.9) 3,477 (36.7) 4,338 (37.3) 4,882 (36.3) 25,380 (38) 1,465 (21.3) 1,695 (21.4) 1,934 (21.6) 1,772 (20.7) 1,957 (20.6) 2,295 (19.8) 2,726 (20.3) 13,844 (20.7) 2,609 (38) 3,059 (38.7) 3,535 (39.5) 3,555 (41.5) 4,049 (42.7) 4,985 (42.9) 5,848 (43.5) 27,640 (41.3) COVID-19 (%) 533 (7.8) 619 (7.8) 682 (7.6) 642 (7.5) 512 (5.4) 685 (5.9) 1,143 (8.5) 4,816 (7.2) 1,784 (26) 2,106 (26.6) 2,467 (27.6) 2,291 (26.7) 1,768 (18.6) 2,089 (18) 3,989 (29.6) 16,494 (24.7) 3,197 (46.5) 3,599 (45.5) 4,037 (45.1) 3,992 (46.6) 4,572 (48.2) 5,540 (47.7) 5,357 (39.8) 30,294 (45.3) 1,357 (19.7) 1,585 (20) 1,766 (19.7) 1,650 (19.2) 2,631 (27.7) 3,304 (28.4) 2,967 (22) 15,260 (22.8) Abbreviations: CDI: Clostridioides difficile infection, SD: standard deviation, CCI: Charlson comorbidity index, ICU: intensive care unit; COVID-19: Coronavirus D, IBD: inflammatory bowel disease Table 2Resource utilization and outcomes of patients with CDI hospitalized in the National Health System and their temporal evolution over the period 2016–20222016201720182019202020212022Totalp-valueMedian LOS (IQR) days13 (17)13 (17)13 (17)12 (17)13 (18)13 (18)13 (16)13 (18)0.082Colectomy (%)No6,832(99.4)7,867(99.5)8,903(99.5)8,541(99.6)9,443(99.6)11,576(99.6)13,408(99.6)66,570(99.6)0.101Yes39 (0.6)42 (0.5)49 (0.5)34 (0.4)40 (0.4)42 (0.4)48 (0.4)294 (0.4)In-hospital all-cause mortality (%)No6,110 (88.9)7,038(89)7,963(89)7,658 (89.3)8,297 (87.5)10,311 (88.8)11,896 (88.4)59,273 (88.7)0.004Yes761(11.1)871(11)989(11)917(10.7)1,186 (12.5)1,307 (11.2)1,560 (11.6)7,591 (11.3)Mean cost (€)8,407.857,971.97,759.788,084.759,254.989,446.598,664.828,580.43< 0.001Abbreviations: LOS: length of stay; IQR: interquartile range Table 2Resource utilization and outcomes of patients with CDI hospitalized in the National Health System and their temporal evolution over the period 2016–20222016201720182019202020212022Totalp-valueMedian LOS (IQR) days13 (17)13 (17)13 (17)12 (17)13 (18)13 (18)13 (16)13 (18)0.082Colectomy (%)No6,832(99.4)7,867(99.5)8,903(99.5)8,541(99.6)9,443(99.6)11,576(99.6)13,408(99.6)66,570(99.6)0.101Yes39 (0.6)42 (0.5)49 (0.5)34 (0.4)40 (0.4)42 (0.4)48 (0.4)294 (0.4)In-hospital all-cause mortality (%)No6,110 (88.9)7,038(89)7,963(89)7,658 (89.3)8,297 (87.5)10,311 (88.8)11,896 (88.4)59,273 (88.7)0.004Yes761(11.1)871(11)989(11)917(10.7)1,186 (12.5)1,307 (11.2)1,560 (11.6)7,591 (11.3)Mean cost (€)8,407.857,971.97,759.788,084.759,254.989,446.598,664.828,580.43< 0.001Abbreviations: LOS: length of stay; IQR: interquartile range Resource utilization and outcomes of patients with CDI hospitalized in the National Health System and their temporal evolution over the period 2016–2022 6,832 (99.4) 7,867 (99.5) 8,903 (99.5) 8,541 (99.6) 9,443 (99.6) 11,576 (99.6) 13,408 (99.6) 66,570 (99.6) 7,038 (89) 7,963 (89) 761 (11.1) 871 (11) 989 (11) 917 (10.7) Abbreviations: LOS: length of stay; IQR: interquartile range CDI as primary or secondary diagnosis CDI was the primary diagnosis coded in 25,973 patients (38.8%), and this percentage increased since 2016. Sepsis, respiratory tract infection, urinary tract infection, heart disease, COVID-19, cancer, and kidney disease were the most common among the more than 3,500 different primary diagnoses in patients with CDI coded as a secondary diagnosis. Comparing CDI as a primary or secondary diagnosis (Table 3), patients with CDI as a primary diagnosis were more commonly women and were older (72 vs. 69 years old, p < 0.001). Conversely, there were more highly comorbid patients among those with secondary CDI (44.6% vs. 36.2%, p < 0.001). Patients with CDI as a secondary diagnosis were more frequently admitted to surgical wards (12.78% vs. 2.27%, p < 0.001) or intensive care units (2.11% vs. 0.4%, p < 0.001). COVID-19 was more common among patients with CDI as secondary diagnosis. No significant difference was observed in the percentage of patients with IBD between the groups. The median LOS and mean cost were more than double in patients with secondary CDI. Table 3Comparison of means, medians and percentages of the characteristics of hospitalized patients with CDI as a primary vs. secondary diagnosisPrimary diagnosis N (%)Secondary diagnosis N (%)p-valueTotal25,973 (38.8)40,891 (61.2)SexMale10,804 (41.6)20,783 (50.83)< 0.001Female15,169 (58.4)20,108 (49.17)Mean age (SD)72 (18.6)69 (20.5)< 0.001Age group< 18 years484 (1.86)1,748 (4.27)< 0.00118–59 years4,543 (17.49)8,006 (19.58)60–69 years3,528 (13.58)6,797 (16.62)70–79 years5,746 (22.12)9,306 (22.76)≥ 8011,672 (44.94)15,034 (36.77)Mean CCI (SD)2.19 (2.12)2.68 (2.22)< 0.001Charlson commorbidity index0–111,638 (44.8)13,742 (33.6)< 0.00124,932 (19)8,912 (21.8)≥ 39,403 (36.2)18,237 (44.6)Hospital wardMedical25,225 (97.14)34,550 (84.58)< 0.001Surgical589 (2.27)5,220 (12.78)ICU104 (0.4)860 (2.11)Others50 (0.2)220 (0.54)Any surgical intervention2,702 (10.4)10,684 (26.13)< 0.001COVID-19481 (1.86)2,563 (6.27)< 0.001IBD985 (3.8)1,617 (3.95)0.303Colectomy43 (0.17)251 (0.61)< 0.001SeverityLow4,401 (16.94)415 (1)< 0.001Moderate11,118 (42.81)5,376 (13.1)High8,914 (34.32)21,380 (52.3)Extreme1,540 (5.93)13,720 (33.6)Median LOS (IQR)8 (8)18 (23)< 0.001Mean cost (€)4,749.68 (2,725.14)11,013.63 (13,570.31)< 0.001Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range Table 3Comparison of means, medians and percentages of the characteristics of hospitalized patients with CDI as a primary vs. secondary diagnosisPrimary diagnosis N (%)Secondary diagnosis N (%)p-valueTotal25,973 (38.8)40,891 (61.2)SexMale10,804 (41.6)20,783 (50.83)< 0.001Female15,169 (58.4)20,108 (49.17)Mean age (SD)72 (18.6)69 (20.5)< 0.001Age group< 18 years484 (1.86)1,748 (4.27)< 0.00118–59 years4,543 (17.49)8,006 (19.58)60–69 years3,528 (13.58)6,797 (16.62)70–79 years5,746 (22.12)9,306 (22.76)≥ 8011,672 (44.94)15,034 (36.77)Mean CCI (SD)2.19 (2.12)2.68 (2.22)< 0.001Charlson commorbidity index0–111,638 (44.8)13,742 (33.6)< 0.00124,932 (19)8,912 (21.8)≥ 39,403 (36.2)18,237 (44.6)Hospital wardMedical25,225 (97.14)34,550 (84.58)< 0.001Surgical589 (2.27)5,220 (12.78)ICU104 (0.4)860 (2.11)Others50 (0.2)220 (0.54)Any surgical intervention2,702 (10.4)10,684 (26.13)< 0.001COVID-19481 (1.86)2,563 (6.27)< 0.001IBD985 (3.8)1,617 (3.95)0.303Colectomy43 (0.17)251 (0.61)< 0.001SeverityLow4,401 (16.94)415 (1)< 0.001Moderate11,118 (42.81)5,376 (13.1)High8,914 (34.32)21,380 (52.3)Extreme1,540 (5.93)13,720 (33.6)Median LOS (IQR)8 (8)18 (23)< 0.001Mean cost (€)4,749.68 (2,725.14)11,013.63 (13,570.31)< 0.001Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range Comparison of means, medians and percentages of the characteristics of hospitalized patients with CDI as a primary vs. secondary diagnosis Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range Colectomy was more frequently performed in patients with CDI as a secondary diagnosis (0.61% vs. 0.17%, p < 0.001). The mean age of the patients who underwent a colectomy was 69.5 years, the median LOS was 28.6 days, and the mean cost was €24,895, with no difference between primary and secondary CDI in these aspects. In-hospital all-cause mortality In-hospital all-cause mortality (Table 4) was higher in patients with CDI as a secondary diagnosis (14.5% vs. 6.4%, p < 0.001) overall and every year of the study period, for both men and women, for all age groups, in medical wards, both in COVID and non-COVID patients, and both in patients with and without IBD. Among the patients with CDI who died during admission, those with CDI as a secondary diagnosis were younger (76.4 s. 81.6 years old, p < 0.001), had a higher comorbidity index (3.3 vs. 3, p < 0.001), longer LOS (20 vs. 11 days, p < 0.001), and higher mean cost (€12,421.51 vs. €7,260.77, p < 0.001). In-hospital all-cause mortality was elevated in patients ≥ 80 years with secondary CDI (19.5%), in COVID-19 patients with secondary CDI (19.7%) and in patients who underwent colectomy (32.56% in primary and 22.31% in secondary CDI). In-hospital all-cause mortality was very elevated and significantly higher in primary than in secondary CDI among patients with extreme overall severity (30.3% vs. 24%, p < 0.001), in patients who underwent colectomy (32.56% vs. 22.31%, p < 0.001), and in the ICU (86.5% vs. 75.1%, p = 0.011). Table 4Analysis of in-hospital all-cause mortality in patients with CDI as a primary or secondary diagnosisPrimary diagnosisN (%)Secondary diagnosisN (%)p-valueTotal1,666 (6.41)5,925 (14.49)< 0.001Year2016173 (6.45)588 (14.04)< 0.0012017193 (6.19)678 (14.15)< 0.0012018219 (5.98)770 (14.55)< 0.0012019249 (6.98)668 (13.34)< 0.0012020245 (7.13)941 (15.56)< 0.0012021259 (5.97)1,048 (14.39)< 0.0012022328 (6.34)1,232 (14.87)< 0.001Sex (%)Male732 (6.78)3,102 (14.93)< 0.001Female934 (6.16)2,823 (14.04)< 0.001Mean age (SD)81.6 (11.3)76.42 (14.4)< 0.001Age group(%)< 181 (0.21)42 (2.4)0.01518–5996 (2.11)625 (7.81)< 0.00160–69132 (3.74)899 (13.23)< 0.00170–79317 (5.52)1,435 (15.42)< 0.001≥ 801,120 (9.6)2,924 (19.45)< 0.001Mean CCI (SD)3.02 (2.23)3.34 (2.39)< 0.001Charlson commorbidity index (%)0–1453 (3.89)1,442 (10.49)< 0.0012311 (6.31)1,126 (12.63)< 0.001≥ 3902 (9.59)3,357 (18.41)< 0.001Hospital ward(%)Medical1,539 (6.1)4,846 (14.03)< 0.001Surgical33 (5.6)395 (7.57)0.085ICU90 (86.54)646 (75.12)0.011Others4 (7.84)33 (14.93)< 0.191Colectomy (%)No1,652 (6.37)5,869 (14.44)< 0.001Yes14 (32.56)56 (22.31)0.148COVID-19 (%)No1,608 (6.31)5,420 (14.14)< 0.001Yes58 (12.03)505 (19.7)< 0.001IBD (%)No1,627 (6.51)5,817 (14.81)< 0.001Yes39 (3.96)108 (6.68)< 0.001Severity (%)Low39 (0.89)33 (7.95)< 0.001Moderate350 (3.15)223 (4.15)< 0.001High810 (9.09)2,372 (11.09)< 0.001Extreme467 (30.32)3,297 (24.03)< 0.001Median LOS (IQR)11 (15)20 (26)< 0.001Mean cost (€)7,260.7712,421.51< 0.001Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index; ICU: intensive care unit; COVID-19: Coronavirus disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range Table 4Analysis of in-hospital all-cause mortality in patients with CDI as a primary or secondary diagnosisPrimary diagnosisN (%)Secondary diagnosisN (%)p-valueTotal1,666 (6.41)5,925 (14.49)< 0.001Year2016173 (6.45)588 (14.04)< 0.0012017193 (6.19)678 (14.15)< 0.0012018219 (5.98)770 (14.55)< 0.0012019249 (6.98)668 (13.34)< 0.0012020245 (7.13)941 (15.56)< 0.0012021259 (5.97)1,048 (14.39)< 0.0012022328 (6.34)1,232 (14.87)< 0.001Sex (%)Male732 (6.78)3,102 (14.93)< 0.001Female934 (6.16)2,823 (14.04)< 0.001Mean age (SD)81.6 (11.3)76.42 (14.4)< 0.001Age group(%)< 181 (0.21)42 (2.4)0.01518–5996 (2.11)625 (7.81)< 0.00160–69132 (3.74)899 (13.23)< 0.00170–79317 (5.52)1,435 (15.42)< 0.001≥ 801,120 (9.6)2,924 (19.45)< 0.001Mean CCI (SD)3.02 (2.23)3.34 (2.39)< 0.001Charlson commorbidity index (%)0–1453 (3.89)1,442 (10.49)< 0.0012311 (6.31)1,126 (12.63)< 0.001≥ 3902 (9.59)3,357 (18.41)< 0.001Hospital ward(%)Medical1,539 (6.1)4,846 (14.03)< 0.001Surgical33 (5.6)395 (7.57)0.085ICU90 (86.54)646 (75.12)0.011Others4 (7.84)33 (14.93)< 0.191Colectomy (%)No1,652 (6.37)5,869 (14.44)< 0.001Yes14 (32.56)56 (22.31)0.148COVID-19 (%)No1,608 (6.31)5,420 (14.14)< 0.001Yes58 (12.03)505 (19.7)< 0.001IBD (%)No1,627 (6.51)5,817 (14.81)< 0.001Yes39 (3.96)108 (6.68)< 0.001Severity (%)Low39 (0.89)33 (7.95)< 0.001Moderate350 (3.15)223 (4.15)< 0.001High810 (9.09)2,372 (11.09)< 0.001Extreme467 (30.32)3,297 (24.03)< 0.001Median LOS (IQR)11 (15)20 (26)< 0.001Mean cost (€)7,260.7712,421.51< 0.001Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index; ICU: intensive care unit; COVID-19: Coronavirus disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range Analysis of in-hospital all-cause mortality in patients with CDI as a primary or secondary diagnosis Age group (%) Hospital ward (%) Abbreviations: SD: Standard deviation, CCI: Charlson comorbidity index; ICU: intensive care unit; COVID-19: Coronavirus disease, IBD: inflammatory bowel disease, LOS: length of stay, IQR: Interquartile range The multivariable analysis included year, sex, age, CCI, hospital ward, COVID-19, IBD, primary or secondary diagnosis, severity, and LOS (Table 5). It showed a lower risk of in-hospital all-cause mortality in patients with CDI as primary diagnosis compared to secondary diagnosis (OR 0.74). Increasing age was associated with in-hospital all-cause mortality (OR 1.04). Higher CCI was also associated with in-hospital all-cause mortality (OR 1.14). Compared to other hospital wards, ICU admission was associated with higher all-cause mortality (OR 28.54). Regarding severity, moderate (OR 1.54), high (OR 3.77) and extreme severity (OR 10.39) were associated with higher in-hospital all-cause mortality than low global severity. Neither year of diagnosis, sex, COVID-19, nor IBD had a significant impact on in-hospital all-cause mortality in the multivariable analysis. Table 5Multivariable analysis of factors associated with in-hospital all-cause mortality in patients with CDIIn-hospital all-cause mortalityPrimary diagnosisSecondary diagnosisAny positionaOR (95%CI)aOR (95%CI)aOR (95%CI)Year0.98 (0.96–1.01)0.98 (0.97-1.00)0.98 (0.96-1)SexFemale111Male0.99 (0.89–1.11)1.02 (0.96–1.08)1.01 (0.96–1.07)Age1.05 (1.05–1.06)1.03 (1.03–1.04)1.04 (1.04–1.04)CCI1.1 (1.07–1.13)1.15 (1.13–1.17)1.14 (1.13–1.15)Hospital wardMedical1.3 (0.44–3.86)0.98 (0.66–1.44)0.98 (0.68–1.4)Surgical1.64 (0.52–5.19)0.68 (0.45–1.02)0.70 (0.48–1.03)ICU116.9 (32.04-426.52)24.89 (16.30–38.00)28.54 (19.12–42.69)Others111COVID-190.98 (0.72–1.33)0.96 (0.86–1.08)0.95( (0.85–1.06)IBD0.99 (0.69–1.42)0.84 (0.67–1.03)0.88 (0.73–1.07)Primary diagnosis0.74 (0.6–0.79)SeverityLow111Moderate2.19 (1.56–3.07)0.46 (0.31–0.69)1.54 (1.20–1.98)High5.6 (4.01–7.81)0.95 (0.65–1.39)3.77 (2.96–4.81)Extreme22.19 (15.67–31.43)2.45 (1.67–3.60)10.39 (8.12–13.30)LOS1.01 (1.00-1.02)1.00 (1.00-1.01)1.00 (1.00-1.01)Abbreviations: aOR: adjusted odds ratio, CI: confidence interval, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay Table 5Multivariable analysis of factors associated with in-hospital all-cause mortality in patients with CDIIn-hospital all-cause mortalityPrimary diagnosisSecondary diagnosisAny positionaOR (95%CI)aOR (95%CI)aOR (95%CI)Year0.98 (0.96–1.01)0.98 (0.97-1.00)0.98 (0.96-1)SexFemale111Male0.99 (0.89–1.11)1.02 (0.96–1.08)1.01 (0.96–1.07)Age1.05 (1.05–1.06)1.03 (1.03–1.04)1.04 (1.04–1.04)CCI1.1 (1.07–1.13)1.15 (1.13–1.17)1.14 (1.13–1.15)Hospital wardMedical1.3 (0.44–3.86)0.98 (0.66–1.44)0.98 (0.68–1.4)Surgical1.64 (0.52–5.19)0.68 (0.45–1.02)0.70 (0.48–1.03)ICU116.9 (32.04-426.52)24.89 (16.30–38.00)28.54 (19.12–42.69)Others111COVID-190.98 (0.72–1.33)0.96 (0.86–1.08)0.95( (0.85–1.06)IBD0.99 (0.69–1.42)0.84 (0.67–1.03)0.88 (0.73–1.07)Primary diagnosis0.74 (0.6–0.79)SeverityLow111Moderate2.19 (1.56–3.07)0.46 (0.31–0.69)1.54 (1.20–1.98)High5.6 (4.01–7.81)0.95 (0.65–1.39)3.77 (2.96–4.81)Extreme22.19 (15.67–31.43)2.45 (1.67–3.60)10.39 (8.12–13.30)LOS1.01 (1.00-1.02)1.00 (1.00-1.01)1.00 (1.00-1.01)Abbreviations: aOR: adjusted odds ratio, CI: confidence interval, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay Multivariable analysis of factors associated with in-hospital all-cause mortality in patients with CDI Abbreviations: aOR: adjusted odds ratio, CI: confidence interval, CCI: Charlson comorbidity index, ICU: Intensive Care Unit, COVID-19: Coronavirus Disease, IBD: inflammatory bowel disease, LOS: length of stay Discussion The burden of CDI in hospitalized patients is a cause for concern in healthcare systems. This study analyzed the characteristics of CDI in hospitals in Spain and its trend over recent years, confirming an increase in both primary and secondary diagnoses. The results have notable importance, especially at the national level. A previous MBDS-based study [10] reported approximately 49,000 CDI cases over 15 years with a mean prevalence of 7.4 cases per 100,000 population, compared to the mean prevalence of 20.3 cases per 100,000 population found in this study. Although part of the increase might be explained by improvements in diagnostic tests and clinical awareness, it seems clear that the overall prevalence continues to grow. Data from a point prevalence survey of hospitalized patients in Spain (EPINE) also showed an exponential increase from 2012 to 2019 [9]. Comparisons among countries are challenging owing to differences in reporting. Nonetheless, our hospital-based data remain lower than those described in other European countries, the US, and Canada [14]. A systematic review including studies from 41 countries showed an overall rate of healthcare facility-associated CDI of 2.24 per 1,000 admissions [7], close to the 2.17 cases per 1,000 admissions found in our study. The population-based incidence of CDI has also increased, surpassing the reported 16 and 19 cases per 100,000 population in England and Scotland, respectively, but still far from the 61, 74 and 110 cases per 100,000 population in Sweden, Finland, and the US, respectively. Among countries with publicly available data compared in a narrative review, the incidence of CDI among hospitalized patients declined the most in the US [14]. Our data show that both hospital-based and population-based CDI cases experienced a decrease in 2019; however, this trend was inverted in 2020 and thereafter. During the COVID-19 pandemic, a decrease in hospital-acquired CDI was reported, although there are studies with different results [19]. A retrospective analysis in Romania found that patients coinfected with CDI and COVID-19 had worse outcomes than pre-pandemic CDI patients [20]. While social distancing and enhanced contact precautions may have contributed to a decline in CDI, the higher use of antimicrobials and overwhelmed healthcare systems might have acted in the opposite direction. A decline in testing may also have influenced the decrease in CDI during the pandemic. Central-line associated blood stream infections, catheter-related urinary tract infections, and MRSA bacteremia increased as the COVID-19 burden increased in US hospitals, whereas this was not the case for CDI [13]. No decrease in CDI was observed during the pandemic in Denmark [21] or Greece [22], and a single-center study in Spain showed an increase in healthcare-onset CDI from 2019 to 2022 [23]. Some decrease in CDI rates during the pandemic can be attributed to the decline in hospitalizations. The number of hospital admissions in Spain decreased from 4.5 million in 2019 to 4.0 million in 2020 but increased in 2021 and 2022, almost reaching the previous figures. The increase in CDI cases in Spanish hospitals could also be related to the growing use of PCR for diagnosis of CDI. There were a higher number of cases of CDI in women in the present study, as reported in other studies [5, 6, 10]; however, in-hospital all-cause mortality did not differ between the sexes. Future research should explore whether there are differences in clinical features and outcomes in this regard. With respect to age, we confirmed a higher incidence of CDI in the elderly, similar to that previously described [4, 7]. Although the mean age in this study was lower than that reported in the ECDC epidemiological report [6], the mean age of hospitalized patients with CDI continues to increase, which is concerning and reflects the aging population in our healthcare systems. Our results also show that comorbidities in hospitalized patients with CDI have increased, warranting special attention to avoid infection in this susceptible population. IBD is a known risk factor for CDI and is associated with worse outcomes [24, 25]. In our study, almost 4% of CDI cases occurred in patients with IBD, a disease present in less than 1% of the Spanish population [26]. Colectomies were more common in patients with IBD, representing > 10% of all colectomies. IBD did not show an independent role in mortality in the multivariable analysis. Whether these patients were younger, less comorbid, or treated by more specialized teams was not analyzed. The possible influence of modern immunomodulating therapies on the risk and evolution of CDI in patients with IBD should be assessed in future studies. Almost two thirds of CDI cases in this study were coded as secondary when the infection developed in patients admitted for other conditions (mainly infectious diseases), similar to previous reports [5, 6, 9, 10]. While secondary CDI represent HA-CDI, there might be community acquired cases presenting during admission. And among primary cases, there are probably not only CA-CDI cases but also cases of undetermined origin and readmissions due to CDI acquired in a previous hospitalization; this information could not be retrieved from the MBDS. In this regard, comparisons between primary and secondary cases must be interpreted with caution. Secondary CDI peaked in 2020 and was also higher in 2021 and 2022 than in previous years; therefore, we have most likely witnessed the effects of the high use of antibiotics in the context of the COVID-19 pandemic. Two recent studies described the features of primary and secondary CDI. In Vehreschild et al. [5]. patients with primary CDI were more frequently women, slightly younger, and mostly treated in Internal Medicine departments; the average severity in the medical-economic classification system was half that of the secondary cases and, in parallel, LOS and in-hospital mortality were lower. Patients with primary CDI in Esteban-Vasallo et al. [10]. were older and had lower CCI, LOS, and cost. Our study confirms a differentiated pattern in primary vs. secondary CDI, with primary cases mostly older patients admitted to medical wards and secondary cases younger patients with higher CCI, admitted to surgical wards and ICU with longer LOS, factors that contribute to the acquisition and development of the infection. Comorbidities seem to play a more important role than age in the risk of developing CDI in the hospital, as shown in a recent point prevalence survey in Spain describing renal failure, cancer, diabetes, immunodeficiency, and liver cirrhosis as factors involved [9]. Colectomies were more common among patients with secondary CDI, especially between 60 and 79 years of age. Despite being younger, in-hospital all-cause mortality in these patients was high, as previously reported, likely reflecting the severity of infection [27, 28]. The in-hospital all-cause mortality rate in patients with CDI in this study was similar to that described previously in Spain [10]. Higher mortality rates in patients with secondary CDI have also been described in French and German hospitals [4, 5]. Age, comorbidity, ICU admission, overall severity, and secondary diagnosis predicted in-hospital all-cause mortality in patients with CDI. An overall mortality of 20.7% has been reported among patients with a diagnosis of CDI during admission to acute care European hospitals, including 3.5% of cases possibly or definitely related to CDI [1]. More recently, the overall mortality rate reported in Europe was 14.4% to 15.9% between 2018 and 2020, with 2.8-5% related to CDI [6]. The severity of CDI and the cause of death were not available in our study; thus, the role of the infection itself in mortality is uncertain. Fragility must be considered in these patients, as it can influence outcomes. A recent study implemented the Hospital Frailty Risk Score in more than 90,000 patients hospitalized for primary CDI; frail patients (58% of the sample) had higher rates of fulminant CDI, colectomy, ICU admission, longer LOS, and in-hospital mortality [29]. The median LOS in patients with CDI was 13 days, compared to less than 7 days for overall admissions in Spanish hospitals [30]. LOS was longer in secondary CDI and remained stable throughout the study period, similar to that observed in German hospitals [5]. A longer LOS reflects the severity of the patient´s condition and entails higher exposure to C. difficile spores and antibiotics. The mean cost per admission, which was highest in 2020 and 2021, concurring with most of the COVID-19 pandemic, has almost doubled that reported in Spain in previous years [10]. Thus, CDI causes a high burden on the healthcare system in terms of LOS and cost. Although a separate analysis of the cost for first episodes versus recurrences was not available, the data shown are worth noting, given that cost in CDI is mainly associated with expenditure due to prolonged hospitalization. Limitations The present study has limitations inherent to the use of administrative database. First, although CDI is easily identified per ICD-10-CM, other data from hospital discharge reports could be influenced by incomplete or variable codification among centers. There is a potential risk that some cases coded as primary correspond to HA-CDI from previous admissions and are actually secondary cases. In addition, owing to the source of the data, some clinical variables and information, such as previous antibiotic exposure, microbiological data, treatment, and recurrence, were lacking. As mentioned before, the severity of CDI and the cause of death could not be retrieved. Nonetheless, this study included a high number of CDI cases over seven years with a fair amount of detail, thus contributing important epidemiological information. The significant burden of morbidity, mortality, and health expenditure in patients with CDI, which continues to increase, warrants continuous monitoring of its behaviour in our hospitals. A better understanding of this infection benefits from robust and accurate information, and the importance of coding cannot be overemphasized. Further research, including clinical and microbiological information, will complement the valuable findings provided by epidemiological data.